2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Glioblastoma
7
Melanoma
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Breast Neoplasms
2
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Glioma
1
Chemotherapy;Advanced Gastric Cancer;Cisplatin;Disulfiram
1
Interventions
Cisplatin
13
Etoposide
11
Paclitaxel
8
Cyclophosphamide
7
Carboplatin
7
Ifosfamide
6
etoposide phosphate
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
pembrolizumab
4
fludarabine
4
Sirolimus
4
Bleomycin
4
fludarabine phosphate
3
Sunitinib
3
Oxaliplatin
3
Mesna
3
Melphalan
3
Filgrastim
3
Drug Therapy
3
Brentuximab Vedotin
3
Bevacizumab
3
Automobiles
3
130-nm albumin-bound paclitaxel
3
tremelimumab
2
sodium thiosulfate
2
ribociclib
2
pralsetinib
2
pegfilgrastim
2
lutetium Lu 177 dotatate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
Disulfiram
×
Clear all
NCT03950830
2023-10-04
DISGCT
National Cancer Institute, Slovakia
Phase 2
Completed
12 enrolled